CDP collaboration on pen-injector technology with the Stevanato Group
Cambridge Design Partnership (CDP), a UK and US based leading technology and product design partner, and the Stevanato Group, a leading producer of glass primary packaging and provider of integrated capabilities for combination products, today announced a collaboration agreement for the development of a new pen-injector based on the Axis-D technology and intellectual property (IP) licensed exclusively from Haselmeier in 2019.
The collaboration between CDP and the Stevanato Group strongly supports the expansion of the Stevanato group’s portfolio of devices for patients suffering from diabetes.
The agreement leverages the mutual strengths: on one side, CDP’s leading design and development expertise in drug delivery and on the other, the Stevanato Group’s extensive experience in glass containers, tooling, injection moulding, device assembly, and its global commercial network.
CDP and the Stevanato Group will be able to offer innovative drug delivery solutions to pharmaceutical customers working together from the first concept right through design development, scale-up, regulatory submission, and commercial-scale production in all global markets.
“We are delighted to be announcing this partnership,” says Uri Baruch, CDP’s Head of Drug Delivery. “The Stevanato Group is well established in the device field as a leading supplier of cartridges and assembly equipment for pen-injectors. It is a pleasure to extend our existing working relationship with them for their pen-injector and to address the needs of patients.”
“Our R&D team – with the active support of CDP, an established player in the design and development of drug delivery devices – will offer a competitive pen-injector platform and some customization options,” comments Paolo Patri, Chief Technology Officer at the Stevanato Group. “With the resources and experience of both companies, we will provide diabetic patients with a product that is easy-to-use, aesthetically appealing, and cost-effective.”
This new collaboration is one of the programmes behind the recent, substantial growth of CDP’s team of healthcare-focused designers and engineers in both Cambridge (UK) and Raleigh, NC (USA) facilities. “This is another strong vote of confidence in CDP. We look forward to this being the first of many end-to-end projects that we can collaborate on in this new partnership”, says Uri Baruch.
About Cambridge Design Partnership: Cambridge Design Partnership is an employee-owned technology and product design partner, located in Cambridge (UK) and Raleigh, North Carolina (US), focused on helping clients grow their business. Over more than 20 years, some of the world’s largest and most innovative companies have trusted CDP with their most important product development programs. CDP provide an integrated and holistic product development capability through a highly qualified team, well equipped development labs and ISO 13485/9001 approved methods. This encompasses research and strategy, design, technology and digital innovation, product development and regulatory and manufacturing support. CDP experts are able to take combination products through a full design cycle and submission, enabling customers to launch products that are user-centric and commercially effective. For more information, please visit www.cambridge-design.com
For further information and media enquiries, please contact: firstname.lastname@example.org or call 01223 264428
About the Stevanato Group: Established in 1949, the Stevanato Group is the world’s largest, privately-owned designer and producer of glass primary packaging for the pharmaceutical industry. From its outset, the Group has developed its own glass converting technology to ensure the highest standards of quality. The Group comprises a wide set of capabilities dedicated to serving the biopharmaceutical and diagnostic industries: from glass containers with its historical brand Ompi, to high-precision plastic diagnostic and medical components, to contract manufacturing for drug delivery devices, to vision inspection systems, assembly, and packaging equipment. The Group also provides analytical and testing services to study container closure integrity and integration into drug delivery devices, streamlining the drug development process. Thanks to its unique approach as a one-stop-shop, the Stevanato Group can offer an unprecedented set of solutions to biopharma companies for a faster time to market and a reduced total cost of ownership. For more information, please visit www.stevanatogroup.com
For all enquiries, please contact Steven Kaufman
Partner & Head of Drug Delivery